Top Banner
Head & Neck and ENT Newsletter May 2015 Oromouth is now also closed to females aged 35-44 as we are fully recruited in this age group Accelerated - We have recruited 16 patients this month, which is the highest monthly figure to date. Thank you to all the head and neck surgeons for your help in achieving this Coast is now closed to recruitment for the head and neck tumour site group of patients Hawk -The 1 st patient has consented for pre- screening We are the 1 st in Europe! OTO-104 is now in follow-up and closed to recruitment
6

Head & Neck and ENT May 2015.pdf · PI Dr. A Hartley Determination ofearly and late toxicity events in treatment HPV positive oropharyngeal SCC using cetuximab vs. cisplatin 0 26

Mar 23, 2020

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Head & Neck and ENT May 2015.pdf · PI Dr. A Hartley Determination ofearly and late toxicity events in treatment HPV positive oropharyngeal SCC using cetuximab vs. cisplatin 0 26

Head & Neck and ENT

Newsletter May 2015

Oromouth is now also closed to

females aged 35-44 as we are fully

recruited in this age group

Accelerated - We have recruited 16 patients

this month, which is the highest monthly

figure to date.

Thank you to all the head and neck surgeons

for your help in achieving this

Coast is now closed to

recruitment for the head

and neck tumour site group

of patients

Hawk -The 1st patient

has consented for pre-

screening

We are the 1st in

Europe!

OTO-104 is now

in follow-up and

closed to

recruitment

Page 2: Head & Neck and ENT May 2015.pdf · PI Dr. A Hartley Determination ofearly and late toxicity events in treatment HPV positive oropharyngeal SCC using cetuximab vs. cisplatin 0 26

Head & Neck and ENT

Newsletter May 2015

Acronym Details Recruitment

(month)

Recruitment

(total)

Accelerated

PI Prof. H Mehanna

Accelerated development of novel and personalised treatments using new

and repurposed therapeutic agents and individualised treatment selection

and monitoring 16 50

AMPACT2

PI Mr. P Monksfield

A TACTT3 study extension evaluating the safety of repeated quarterly

treatment cycles with AM-101 for acute peripheral tinnitus 0 4

ART DECO

PI Dr. P Sanghera

Investigating dose escalated IMRT in locally advanced laryngeal and

hypopharyngeal cancers without unacceptable toxicity increases 0 30

BUTTERFLY

PI Mr. P Monksfield

Post-market follow-up on the Cochlear™ Baha® Attract System

(magnetic bone conduction implant) for Baha surgery candidates 0 14

Cost Effectiveness of BAHA

PI Mr. P Monksfield

Assessing the benefit to patients of BAHA implantation and the cost

effectiveness of using this device within the NHS 0 238

TRIALS CURRENTLY OPEN

Page 3: Head & Neck and ENT May 2015.pdf · PI Dr. A Hartley Determination ofearly and late toxicity events in treatment HPV positive oropharyngeal SCC using cetuximab vs. cisplatin 0 26

Head & Neck and ENT

Newsletter May 2015

Acronym Details Recruitment

(month)

Recruitment

(total)

De-ESCALaTE HPV

PI Dr. A Hartley

Determination of early and late toxicity events in treatment of HPV

positive oropharyngeal SCC using cetuximab vs. cisplatin 0 26

ElaTION

PI Prof. H Mehanna

A randomised study investigating study looking at the efficacy and cost

effectiveness of real time ultrasound elastography in the investigations

of thyroid nodules and the diagnosis of thyroid cancer 0 0

Hawk

PI Dr. J. Good

A phase II study of MEDI4736 monotherapy in patients with recurrent

or metastatic SCC who have progressed after second line platinum

treatment (PD-L1 positive) 0 0

HOPON

PI Mr. P Praveen

A randomised controlled trial investigating the use of hyperbaric

oxygen to prevent osteoradionecrosis of the irradiated mandible 0 11

IoN

PI Prof. H Mehanna

A phase II/III trial investigating the necessity of ablative radio-iodine for

treatment of low risk differentiated thyroid cancer patients 0 0

NIMRAD

PI Dr. A Hartley

A phase III trial determining whether HNSCC patients unsuitable for

cisplatin/cetuximab can benefit from nimorazole with standard RT 0 7

TRIALS CURRENTLY OPEN

Page 4: Head & Neck and ENT May 2015.pdf · PI Dr. A Hartley Determination ofearly and late toxicity events in treatment HPV positive oropharyngeal SCC using cetuximab vs. cisplatin 0 26

Head & Neck and ENT

Newsletter May 2015

Acronym Details Recruitment

(month)

Recruitment

(total)

OROMOUTH

PI Mr. S Ahmed

Determining the prevalence of HPV in the mouth and oropharynx of the

tonsillectomy population using tonsils, oral fluid, blood and urine 3 191

QUIET

PI Miss. R Banga

A Balanced Randomised Placebo Controlled Double-blind Phase IIa

Study to Investigate the Efficacy and Safety of AUT00063 Versus

Placebo in Subjective Tinnitus. 2 13

RAPPER

PI Dr. A Hartley

Assessing the association between DNA polymorphisms and individual

patient variability in normal tissue radiation response and toxicity 0 25

SEND

PI Mr. P Praveen

Investigating the role of selective neck dissection for patients with early

oral SCC (T1/T2) and no clinical evidence of lymph node metastases 0 28

TACTT3

PI Mr. P Monksfield

A phase III trial to evaluate the efficacy of repeated AM-101

(esketamine hydrochloride) gel injections for acute peripheral tinnitus 0 13

TRIALS CURRENTLY OPEN

Page 5: Head & Neck and ENT May 2015.pdf · PI Dr. A Hartley Determination ofearly and late toxicity events in treatment HPV positive oropharyngeal SCC using cetuximab vs. cisplatin 0 26

Head & Neck and ENT

Newsletter May 2015

Acronym Details

CompARE

PI Prof. H Mehanna

A phase III 4 arm randomised controlled trial comparing alternative regimens for escalating treatment of higher-risk

oropharyngeal cancer

Condor

PI Dr. A Kong

A phase II randomised study of MEDI4736 monotherapy, tremelimumab monotherapy and MEDI4736 in combination

with tremelimumab in patients with recurrent or metastatic SCC who have progressed after second line platinum

treatment (PD-L1 negative)

DAHANCA-21

PI Mr P Praveen

Hyperbaric oxygen treatment of mandibular osteoradionecrosis. A randomised, clinical study.

EORTC

PI Prof. H Mehanna

An international phase IV field study for the reliability and validity of the EORTC Head and Neck Cancer Module

H&N43

PENDING TRIALS

Page 6: Head & Neck and ENT May 2015.pdf · PI Dr. A Hartley Determination ofearly and late toxicity events in treatment HPV positive oropharyngeal SCC using cetuximab vs. cisplatin 0 26

Head & Neck and ENT

Newsletter May 2015

Institute of Head and Neck Studies and Education (InHANSE) School of Cancer Sciences

Robert Aitken Building, 2nd Floor

University of Birmingham

B15 2TT, UK

www.inhanse.org

Thank you for your continued support!

Any comments or suggestions?

Please forward to [email protected]